Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
May 23 2024 - 8:30AM
Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company
advancing a new class of nanomedicine therapeutics that traverse
tissue barriers to selectively target activated cells in regions of
inflammation, today announced that the company will present
preclinical data at the upcoming Consortium of Multiple Sclerosis
Centers (CMSC) and Society of Nuclear Medicine & Molecular
Imaging 2024 annual meetings. The presentations will demonstrate
the therapeutic potential of Ashvattha’s novel CSF1R dendranib for
MS, based on symptom reduction in a mouse experimental autoimmune
encephalitis (EAE) model of MS. Additionally, the presentation by
Ashvattha’s collaborators at Stanford University will demonstrate
reduction in neuroinflammation following CSF1R dendranib treatment
by PET imaging using Ashvattha’s proprietary 18F-OP-801
radioimaging agent.
Details for the presentations are as
follows:
CMSC Annual Meeting 2024
May 29 – June 1, 2024Music City
Center, Nashville, TN
Poster Title: A
Novel ‘Dendranib’ Inhibiting CSF1R Tyrosine Kinase (H74DS3M8) is an
Immunomodulatory and Anti-Inflammatory Agent that Attenuates EAE
and Promotes Disease ImprovementPoster Board
Label: DMT41Presenter: S. Sakura Minami,
Ph.D., Ashvattha TherapeuticsDate/Time: Thursday,
May 30, 2024, 5:00-7:00 p.m. CT
SNMMI Annual Meeting 2024
June 8-11, 2024Metro Toronto
Convention Center, Toronto, ON, Canada
Presentation Title:
Early detection and tracking of activated macrophages and microglia
in a mouse model of multiple sclerosis using 18F-OP-801 PET imaging
before and after a novel immunomodulatory drugSession
Title: Brain Imaging Council Young Investigator
AwardPresenter: Renesmee C. Kuo in Michelle James
Lab at Stanford UniversityDate/Time: Saturday,
June 8, 2024, 2:05-2.15 p.m. ET
About Ashvattha Therapeutics Ashvattha
Therapeutics is advancing a new class of clinical-stage
nanomedicine therapeutics that traverse tissue barriers to
selectively target activated cells only in regions of inflammation.
Our targeted nanomedicine approach seeks to redefine precision
medicine, empowering a new standard of care across ophthalmology,
neurology, and inflammation. For more information,
visit: www.avttx.com
Media ContactMichael FitzhughLifeSci
Communicationsmfitzhugh@lifescicomms.com628-234-3889